Welcome, everybody. Welcome to episode 555 of the Divine Intervention Podcasts. In today's podcast, we're going to be continue in our series on the free 137 for step three.

This is going to be the discussion. This is going to be part three. So I'm be part three so i'm going to be going to be

going through questions 21 to question 30 and um i know this is primarily intended for step

three takers and level three takers but this will also be abundantly useful for people taking step

to k or level two so we're going to pick up from question 21.

And again, if you missed the first two parts, check out episode 548 and 549.

Just check those out.

All right.

So questions 21 or 23 is pretty much talking about a drug ad.

And this drug ad pretty much is examining because you know we see this drug ad it's about like cirrhosis and a bunch of stuff so

what are some just putting things to do when you encounter a drug ad just basic things

kind of skim it and make sure you're picking up on the important concepts and things you're talking about, right?

So first you want to figure out what's the research question.

So the research question here is that, hey, if you're dealing with patients that have cirrhosis and acute bleeding, esotovaryces, you're comparing two things, right?

Either the sclerotherapy or the emergency

podocable shunt. And they're looking at control of bleeding and survival. We know it's a randomized

control trial. We know that there is blinding. We see the full up here in up to 17 years.

And then you always want to look at the patient characteristics. So there's 211 people that have been studied, and we see the criteria for them being included or excluded from the study.

And then, again, we see how many people.

The numbers always matter, right?

Like 106 people got sclerotherapy, 105 got a porto-ivocayvot. So again, those numbers are pretty similar.

And they look at the outcomes they measure, and then you look at the results.

...